225 related articles for article (PubMed ID: 20832103)
41. [Tamoxifen and endometrial disease in patients with breast cancer].
Dalbert DB; Rodríguez de la Peña MM; Figueredo A; Mural J; Bartt O; Subiela R; Rossi C; Bazán G
Medicina (B Aires); 2013; 73(2):97-103. PubMed ID: 23570756
[TBL] [Abstract][Full Text] [Related]
42. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
Jones SE; Cantrell J; Vukelja S; Pippen J; O'Shaughnessy J; Blum JL; Brooks R; Hartung NL; Negron AG; Richards DA; Rivera R; Holmes FA; Chittoor S; Whittaker TL; Bordelon JH; Ketchel SJ; Davis JC; Ilegbodu D; Kochis J; Asmar L
J Clin Oncol; 2007 Oct; 25(30):4765-71. PubMed ID: 17947724
[TBL] [Abstract][Full Text] [Related]
43. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen.
Tesoro MR; Borgida AF; MacLaurin NA; Asuncion CM
Obstet Gynecol; 1999 Mar; 93(3):363-6. PubMed ID: 10074980
[TBL] [Abstract][Full Text] [Related]
44. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen.
Salazar EL; Paredes A; Calzada L
Gynecol Endocrinol; 2005 Dec; 21(6):312-6. PubMed ID: 16390778
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
[TBL] [Abstract][Full Text] [Related]
46. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
Jones SE
Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S41-4. PubMed ID: 16595025
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
48. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; Andersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC
J Clin Oncol; 2012 Mar; 30(7):709-17. PubMed ID: 22042946
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
[TBL] [Abstract][Full Text] [Related]
50. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study.
Achiron R; Lipitz S; Sivan E; Goldenberg M; Horovitz A; Frenkel Y; Mashiach S
Ultrasound Obstet Gynecol; 1995 Aug; 6(2):116-20. PubMed ID: 8535913
[TBL] [Abstract][Full Text] [Related]
51. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.
Cohen I; Tepper R; Rosen DJ; Shapira J; Cordoba M; Dror Y; Altaras M; Beyth Y
Gynecol Oncol; 1994 Oct; 55(1):138-43. PubMed ID: 7959255
[TBL] [Abstract][Full Text] [Related]
52. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Iddon J; Bundred NJ
Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
[TBL] [Abstract][Full Text] [Related]
53. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients.
Menada MV; Papadia A; Lorenzi P; Costantini S; Bertelli GF; Ragni N
Eur J Gynaecol Oncol; 2004; 25(3):321-3. PubMed ID: 15171309
[TBL] [Abstract][Full Text] [Related]
54. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
[TBL] [Abstract][Full Text] [Related]
56. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
59. Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Schochter F; Rack B; Tzschaschel M; Polasik A; Andergassen U; Trapp E; Alunni-Fabbroni M; Schneeweiss A; Müller V; Pantel K; Gade J; Lorenz R; Rezai M; Tesch H; Soeling U; Fehm T; Mahner S; Schindlbeck C; Lichtenegger W; Beckmann MW; Fasching PA; Janni W; Friedl TWP;
Oncol Res Treat; 2018; 41(3):93-98. PubMed ID: 29490302
[TBL] [Abstract][Full Text] [Related]
60. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]